Vaxcyte, Inc.
PCVXNasdaq
$56.20
↑ +0.3%Jul 17 close · end-of-day
Price
1Y↑ +53.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.8B
Enterprise Value
$6.1B
P/E
—
P/S
—
P/B
2.6
EV/EBITDA
—
PEG
—
FCF Yield
-10.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$180.7M
Free Cash Flow (TTM)
-$780.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-6.0%
ROIC
-68.3%
Debt / Equity
—
Net Cash
$1.7B
Return 1Y
+50.4%
Company profile
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials. The company was formerly known as SutroVax, Inc.
- CEO
- Grant E. Pickering
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 160
- Headquarters
- California
- Website
- vaxcyte.com
Management & directors
- Guggenhime AndrewPRESIDENT AND CFO
- Wassil JimCHIEF OPERATING OFFICER
- Pickering GrantCHIEF EXECUTIVE OFFICER
- Cowan ElviaSVP, Finance & CAO
- Dhaliwal Harpreet S.Chief Technical Ops Officer
Roles derived from SEC Form 4 filings.
Earnings
PCVX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$2.30↑ +121.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$89.6M | -$103.7M | -$232.3M | -$468.0M | -$569.5M | -$923.7M |
| Net income | -$89.2M | -$100,077.00 | -$223,485.00 | -$402,266.00 | -$463,927.00 | -$766,628.00 |
| Diluted EPS | -$3.02 | -$1.93 | -$3.44 | -$4.14 | -$3.80 | -$5.63 |
| Operating cash flow | -$46.6M | -$121.4M | -$170.6M | -$296.8M | -$452.6M | -$655.6M |
| Free cash flow | -$47.8M | -$127.9M | -$176.4M | -$312.9M | -$475.1M | -$669.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$153.0M | -$139.9M | -$162.2M | -$180.8M | -$226.2M | -$242.4M | -$274.3M | -$345.9M |
| Net income | -$128.7M | -$103.1M | $326.4M | -$140.7M | -$166.6M | -$212.8M | $519.4M | -$320.6M |
| Diluted EPS | -$1.10 | -$0.83 | -$1.02 | -$1.04 | -$1.22 | -$1.56 | -$1.81 | -$2.30 |
| Operating cash flow | -$121.4M | -$60.7M | -$111.4M | -$166.3M | -$121.2M | -$143.3M | -$224.8M | -$280.6M |
| Free cash flow | -$129.2M | -$65.7M | -$115.4M | -$171.7M | -$123.0M | -$147.1M | -$227.5M | -$282.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | GUGGENHIME ANDREW· PRESIDENT AND CFO | Sale | 7,913 | $57.16 | $452,283.34 | filing |
| 2026-07-06 | GUGGENHIME ANDREW· PRESIDENT AND CFO | Sale | 2,087 | $57.76 | $120,553.47 | filing |
| 2026-07-06 | GUGGENHIME ANDREW· PRESIDENT AND CFO | Option exercise | 10,000 | $5.35 | $53,500.00 | filing |
| 2026-07-01 | Wassil Jim· CHIEF OPERATING OFFICER | Sale | 1,788 | $56.03 | $100,181.64 | filing |
| 2026-07-01 | Wassil Jim· CHIEF OPERATING OFFICER | Sale | 456 | $57.47 | $26,207.69 | filing |
| 2026-07-01 | Wassil Jim· CHIEF OPERATING OFFICER | Option exercise | 516 | $5.35 | $2,760.60 | filing |
| 2026-07-01 | Wassil Jim· CHIEF OPERATING OFFICER | Sale | 6 | $57.82 | $346.92 | filing |
| 2026-06-26 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 9,137 | $55.27 | $504,956.31 | filing |
| 2026-06-26 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 6,683 | $54.28 | $362,719.83 | filing |
| 2026-06-26 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 6,417 | $56.12 | $360,128.46 | filing |
| 2026-06-26 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 602 | $55.30 | $33,288.79 | filing |
| 2026-06-26 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 356 | $55.23 | $19,660.46 | filing |
| 2026-06-26 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 332 | $55.99 | $18,589.68 | filing |
| 2026-06-26 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 312 | $54.35 | $16,955.64 | filing |
| 2026-06-26 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 207 | $54.22 | $11,223.95 | filing |
| 2026-06-26 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 191 | $56.27 | $10,746.81 | filing |
| 2026-06-18 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 22,236 | $52.50 | $1.2M | filing |
| 2026-06-18 | GUGGENHIME ANDREW· PRESIDENT AND CFO | Sale | 10,000 | $53.00 | $530,000.00 | filing |
| 2026-06-18 | GUGGENHIME ANDREW· PRESIDENT AND CFO | Option exercise | 10,000 | $5.35 | $53,500.00 | filing |
| 2026-06-18 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 1,000 | $52.50 | $52,500.00 | filing |
| 2026-06-18 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 1,000 | $52.50 | $52,500.00 | filing |
| 2026-06-18 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Sale | 225 | $52.51 | $11,814.75 | filing |
| 2026-06-18 | PICKERING GRANT· CHIEF EXECUTIVE OFFICER | Option exercise | 225 | $1.79 | $402.75 | filing |
| 2026-06-15 | Drapeau Anne S | Award | 2,265 | $0.00 | $0.00 | filing |
| 2026-06-15 | Lukatch Heath | Award | 2,265 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.